Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3102)	8/21/2002 4:53:21 PM
From: biostruggle	Read Replies (2) \| Respond to of 10345

Still not widely reported, but according to CBS Marketwatch, Ritalin-SR (Ritalin-LA) was approved by the FDA for marketing by Novartis. Elan gets royalties and also manufactures the drug. Approval came just in time for the beginning of the school year. It will be interesting to see how much market this one-a-day drug captures.

To: Icebrg who wrote (3102)	8/22/2002 5:20:29 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Zonegran (Zonisamide) May Be Effective Second-line Treatment for Neuropathic Pain By Peggy Peck Special to DG News SAN DIEGO, CA -- August 21, 2002 -- Results of a small study of patients with neuropathic pain suggest that zonisamide (Zonegran®), a novel antiepileptic drug, may be effective when satisfactory pain control is not achieved with first line medications. Janet Kunz, RN, MS, and Misha-Miroslav Backonja, MD, from the department of neurology, University of Wisconsin Hospital and Clinics, in Madison, Wisconsin, United States, presented the results August 20th at the 10th World Congress on Pain. The researchers enrolled 14 women and four men with neuropathic pain. Nine patients had complex regional pain syndrome, four had peripheral neuropathy, and five had various other types. Mean age was 46.9 years. Sixteen patients were taking at least one other medication for neuropathic pain. The mean pre-zonisamide pain rating was 6 (range 3.5 to 10). Patients were treated with zonisamide 100 to 500 mg per day and rated their pain on a 0-10 scale (0=no pain, 10=worst pain imaginable) at baseline and after reaching maintenance dosage, Dr. Backonja said. Eight patients (44.4 percent) experienced a mean 3.2-point decrease in pain symptoms on zonisamide and six patients experienced a 1 to 2 point decrease in pain symptoms. Two patients had no improvement in pain symptoms and two patients had an increase in pain symptoms while taking zonisamide. Eleven patients experienced adverse events, including dizziness, nausea/vomiting, mental cloudiness, tiredness, constipation, heat intolerance/sweating, decreased sense of taste and sedation. Based on these results, double-blind, placebo-controlled studies of zonisamide for neuropathic pain are warranted, Dr. Backonja concluded. Elan Pharmaceuticals, Inc. funded the study. docguide.com